EFFECT OF LOSARTAN/HYDROCHLOROTHIAZIDE ON DIASTOLIC FUNCTION IN PATIENTS WITH HYPERTENSION AND CHRONIC STABLE CORONARY ARTERY DISEASE  by Oe, Hiroki et al.
Prevention
E1639
JACC March 27, 2012
Volume 59, Issue 13
EFFECT OF LOSARTAN/HYDROCHLOROTHIAZIDE ON DIASTOLIC FUNCTION IN PATIENTS WITH 
HYPERTENSION AND CHRONIC STABLE CORONARY ARTERY DISEASE
ACC Moderated Poster Contributions
McCormick Place South, Hall A
Sunday, March 25, 2012, 9:30 a.m.-10:30 a.m.
Session Title: Stiff Hearts and Stiff Vessels: The Hypertensive Patient
Abstract Category: 7. Prevention: Hypertension
Presentation Number: 1180-112
Authors: Hiroki Oe, Hiroshi Ito, Norihisa Toh, Katsuomi Iwakura, Katsuhisa Ishii, Hiroyuki Watanabe, Kenei Shimada, Junichi Yoshikawa, Okayama 
University, Okayama, Japan
Background: Hypertension and coronary artery disease (CAD) is associated with an increased risk of heart failure with preserved ejection 
fraction (HFpEF). This subgroup analysis of the Effect of angiotensin receptor blocker (ARB)/Diuretics on diastolic function in patients with 
hypertension (EDEN) trial evaluated the efficacy of changing angiotensin converting enzyme inhibitor (ACEi) or ARB to a combination of Losartan/ 
hydrochlorothiazide (HCTZ) on left ventricular preload and relaxation in hypertensive patients with CAD.
Methods: We enrolled 363 hypertensive patients (232 Men, mean age 68±10 years) with diastolic dysfunction and preserved left ventricular (LV) 
systolic function (ejection fraction > 50%) who had not achieved treatment goal with standard doses of ACEi or ARB. We changed ACEi or ARB to a 
combination of Losartan/HCTZ and followed patients for 24 weeks, and examine a change in septal mitral annular velocity during diastole (e’) and 
the ratio of mitral inflow velocity to e’ velocity (E/e’) from the baseline to the end of follow-up. We investigated whether the complicating CAD affect 
the efficacy of Losartan/HCTZ on diastolic function.
Results: There were 95 patients with CAD (21 with previous myocardial infarction, 74 with stable angina) in our study population. CAD patients 
were older (67±10 vs. 70±9, P=0.0021), and had more comorbid disorders (diabetes, chronic kidney disease) compared to non-CAD patients. NYHA 
class and brain natriuretic peptide level (40±40 vs. 72±124 pg/dL, p=0.0046) was higher in CAD patients. Systolic and diastolic blood pressure 
reduced by 22 and 9 mmHg respectively at the end of follow-up, the e’ velocity significantly increased (5.3±1.4A5.8±1.7cm/s, p<0.0001), and the 
E/e’ ratio significantly decreased (12.8±4.1A11.4±3.9cm/s, p<0.0001) in patients with CAD. The degree of improvement of LV relaxation is more 
evident in non-CAD patients.
Conclusions: The Losartan/HCTZ combination regimen resulted in significant and clinically meaningful additional reductions in blood pressure 
in patients with diastolic dysfunction and preserved LV systolic function. Losartan/HCTZ is also associated with improvement of LV relaxation in 
patients with CAD.
